A randomised, open-label phase 3 study of combination amivantamab and carboplatin-pemetrexed therapy, compared with carboplatin-pemetrexed, in patients with EGFR Exon 20ins mutated locally advanced or metastatic non-small cell lung cancer (PAPILLON)

  • Richardson, Gary (Primary Chief Investigator (PCI))
  • Lai, Li Hoon (Project Manager)

Project: Research

Project Details

Effective start/end date1/03/2131/12/24


  • Medical oncology
  • Lung cancer
  • Clinical trial